Hospices Civils De Lyon

Research at Hospices Civils De Lyon focuses on innovative diagnostic tools and therapeutic devices to enhance patient care across multiple conditions.

• Development of imaging biomarkers for skin diseases
• Validation of point‑of‑care testing for metabolic markers
• Integration of AI‑driven analysis in trial monitoring
• Assessment of novel delivery systems for topical agents

Thirty‑one investigators collaborate within fourteen active studies to bring these technologies to clinical use.

Trials evaluate new antimicrobial strategies and supportive therapies to combat hospital‑acquired infections.

• Adjunctive immunotherapy for ventilator‑acquired pneumonia
• Optimization of antibiotic stewardship protocols
• Antifungal prophylaxis in immunocompromised patients
• Rapid diagnostic assays for bacterial pathogens

The department leverages intensive‑care expertise to improve outcomes for infected patients.

Research aims to refine cardiovascular risk management and antithrombotic regimens for high‑risk groups.

• Full‑dose anticoagulation versus combined therapy in acute venous thromboembolism
• Diuretic‑based algorithms for uncontrolled hypertension in chronic kidney disease
• Reduction of cardiovascular events in trial participants
• Long‑term safety of novel antiplatelet agents

A multidisciplinary team integrates cardiology insights to address overlapping renal and vascular conditions.

Studies investigate immune‑modulating treatments to control autoimmune skin and systemic disorders.

• Novel biologics for cutaneous lupus erythematosus
• Targeted therapy for hidradenitis suppurativa
• Interferon‑gamma effects on immune response in critical care
• Long‑term safety monitoring of immune‑targeted agents

The dermatology unit at Hospices Civils De Lyon provides dedicated support for these immune‑focused investigations.

Clinical work explores androgen deprivation strategies and novel hormonal agents to improve prostate cancer outcomes.

• Combination of apalutamide with androgen deprivation therapy
• Imaging‑guided treatment planning using PSMA PET
• Pathological complete response rates after surgery
• Metastasis‑free survival assessment

Oncology collaboration within the site supports comprehensive research in high‑risk localized or locally advanced prostate cancer.

Trials target solid tumors with innovative immunotherapy and targeted drug combinations.

• Pembrolizumab plus experimental agents for HPV‑positive head and neck carcinoma
• Checkpoint inhibitors in metastatic settings
• Biomarker‑driven patient selection
• Evaluation of treatment durability and survival outcomes

Multicenter coordination ensures robust data collection across oncologic studies.

Research focuses on metabolic correction and disease‑modifying therapies for rare inherited disorders.

• Lumasiran impact on plasma oxalate in primary hyperoxaluria type 1
• Encaleret effects on calcium homeostasis in autosomal dominant hypocalcemia
• Furosemide protocol to enhance stone‑free rates after ureteroscopy
• Monitoring of metabolic parameters in trial cohorts

Specialized metabolic laboratories support precise measurement of treatment effects.

Investigations assess adjunctive treatments to shorten ventilation time and improve pulmonary outcomes.

• Recombinant interferon‑gamma for ventilator‑acquired pneumonia
• Anti‑inflammatory agents to reduce lung injury
• Advanced respiratory function monitoring tools
• Strategies to reduce intensive‑care unit length of stay

The respiratory team collaborates closely with intensive‑care specialists at the site.

A robust portfolio addresses severe inflammatory skin conditions through novel biologics and therapeutic algorithms.

• Spesolimab efficacy in moderate to severe hidradenitis suppurativa
• Vilobelimab for ulcerative pyoderma gangrenosum
• Litifilimab safety in active cutaneous lupus erythematosus
• Development of personalized treatment pathways for refractory skin disease

The dermatology department at Hospices Civils De Lyon leads these patient‑centered studies.

Studies aim to improve substance‑use management and mental health outcomes through behavioral interventions and pharmacologic support.

• Baclofen for benzodiazepine tapering in dependence
• Evaluation of addiction counseling models
• Assessment of mental health scales in trial participants
• Integration of behavioral therapy with medication regimens

A multidisciplinary approach combines psychiatry, nursing, and psychology expertise to enhance care.